SYRS News and Press, Syros Pharmaceuticals Inc. From 11/14/23

Syros Pharmaceuticals Inc. (SYRS) is expected to report $-1.12 for Q3 2023

2023-11-13 13:05:22 ET More on Syros Pharmaceuticals Syros Pharmaceuticals announces job cuts, CEO change Seeking Alpha’s Quant Rating on Syros Pharmaceuticals Historical earnings data for Syros Pharmaceuticals Financial information for Syros Pharmaceu...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 14, 2023 to report its t...

2023-10-02 09:33:00 ET More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Syros Pharmaceuticals, Inc. (SYRS) Q2 2023 Earnings Call Transcript Syros falls as Pfizer ends collaboration Seeking Alpha’s...

-- Conley Chee, CCO and CBO, to succeed Nancy Simonian, M.D. as CEO; Dr. Simonian to retire as CEO, effective December 1, 2023, and will remain on the Board of Directors -- -- Planned workforce reduction of approximately 35% sharpens focus of organization on late-stage development of tami...

2023-08-16 10:08:58 ET Gainers: Novo Integrated Sciences ( NVOS ) +86% . Aeon Biopharma ( AEON ) +11% . Biophytis ( BPTS ) +10% . Syros Pharmaceuticals ( SYRS ) +9% . MediciNova ( MNOV ) +8% . Losers: Impel Pharmaceuticals...

2023-08-08 11:12:07 ET Syros Pharmaceuticals, Inc. (SYRS) Q2 2023 Earnings Conference Call August 08, 2023 08:30 AM ET Company Participants Karen Hunady - Director, IR and Corporate Communications Nancy Simonian - President and CEO David Roth - CMO Jason Haas...

2023-08-08 07:37:47 ET Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q2 GAAP EPS of $1.30 beats by $2.43 . Revenue of $2.8M (-55.4% Y/Y) misses by $0.7M . Cash, cash equivalents and marketable securities as of June 30, 2023 were $144 million, as compare...

-- On track to announce initial randomized data from SELECT-AML-1 trial in 4Q 2023 -- -- Expect to complete enrollment of 190 patients in SELECT-MDS-1 trial in 4Q 2023; pivotal CR data expected in 3Q 2024 -- -- Management to host a conference call at 8:30 a.m. ET today -- ...

2023-08-07 12:46:32 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$1.13 and the consensus Revenue Estimate is $3.5M (-44.3% Y/Y). Over the last 2 years, ...